FMP

FMP

Enter

ALT - Altimmune, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ALT.png

Altimmune, Inc.

ALT

NASDAQ

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

8.74 USD

-0.27 (-3.09%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. Vipin K. Garg Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryla...

CIK

0001326190

ISIN

US02155H2004

CUSIP

02155H200

Address

910 Clopper Road

Phone

240 654 1450

Country

US

Employee

59

IPO Date

May 26, 2017

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

ALT Financial Summary

CIK

0001326190

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

02155H200

ISIN

US02155H2004

Country

US

Price

8.74

Beta

0.07

Volume Avg.

3.01M

Market Cap

621.63M

Shares

-

52-Week

5.275-14.84

DCF

2.51

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.57

P/B

-

Website

https://altimmune.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest ALT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep